SCHEMBL2967641

SCHEMBL2967641

COCCOc1ccc(-c2oc3ncnc(NCCN4CCNCC4)c3c2-c2ccccc2)cc1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LCK P06239 18/20 0.83
TNK2 Q07912 18/20 0.83
KDR P35968 9/20 0.83
JAK3 P52333 8/20 0.83
EGFR P00533 2/20 0.83
SRC P12931 2/20 0.83
ZAP70 P43403 2/20 0.83
KDM4E B2RXH2 2/20 0.64
ALDH1A1 P00352 2/20 0.64
HPGD P15428 2/20 0.64
TSHR P16473 2/20 0.64
NPSR1 Q6W5P4 2/20 0.64
HSD17B10 Q99714 2/20 0.64
LMNA P02545 1/20 0.64
PKM P14618 1/20 0.64
AURKA O14965 1/20 0.64
USP2 O75604 1/20 0.64
MAPK1 P28482 1/20 0.64
HTT P42858 1/20 0.64
JAK2 O60674 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2968470 0.91 TNK2 (1.00) LCKTNK2KDRJAK3EGFR
SCHEMBL2965913 0.90 TNK2 (1.00) LCKTNK2KDRJAK3EGFR
SCHEMBL2966394 0.89 LCK (1.00) LCKTNK2KDRJAK3EGFR
SCHEMBL3565005 0.87 LCK (0.83) LCKTNK2KDRJAK3EGFR
SCHEMBL2969946 0.85 LCK (0.92) LCKTNK2KDRJAK3EGFR
SCHEMBL2962332 0.84 TNK2 (0.60) LCKTNK2KDRJAK3EGFR
SCHEMBL2975902 0.84 TNK2 (0.79) LCKTNK2KDRJAK3EGFR
SCHEMBL2975444 0.83 LCK (0.89) LCKTNK2KDRJAK3EGFR
SCHEMBL2966416 0.83 TNK2 (0.82) LCKTNK2KDRJAK3EGFR
SCHEMBL2966740 0.83 LCK (0.77) LCKTNK2KDRJAK3EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US claimed
EP-1768986-A2 FURANOPYRIMIDINES Amgen Inc. (US) 2007-04-04 EP claimed
US-20060040961-A1 Furanopyrimidines AMGEN INC. 2006-02-23 US claimed
WO-2006004658-A2 FURANOPYRIMIDINES AMGEN INC. (US) 2006-01-12 WO claimed
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US disclosed
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US disclosed
US-7776867-B2 Furanopyrimidines AMGEN INC. (US) 2010-08-17 US disclosed
US-20060040961-A1 Furanopyrimidines AMGEN INC. 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060040961-A1 Furanopyrimidines TYMS, IDO1, NFATC1 LCK 18/4885TNK2 1075/4885KDR 2200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.